2017 Q3 Form 10-Q Financial Statement
#000143774917019211 Filed on November 14, 2017
Income Statement
| Concept | 2017 Q3 | 2016 Q3 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $520.0K | $500.0K |
| YoY Change | 4.0% | 16.28% |
| % of Gross Profit | ||
| Research & Development | $530.0K | $636.0K |
| YoY Change | -16.67% | 86.51% |
| % of Gross Profit | ||
| Depreciation & Amortization | ||
| YoY Change | ||
| % of Gross Profit | ||
| Operating Expenses | $530.0K | $636.0K |
| YoY Change | -16.67% | 86.51% |
| Operating Profit | -$1.045M | -$1.135M |
| YoY Change | -7.93% | 47.4% |
| Interest Expense | $474.0K | $45.00K |
| YoY Change | 953.33% | 18.42% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$371.0K | $11.00K |
| YoY Change | -3472.73% | -123.91% |
| Pretax Income | -$1.416M | -$1.124M |
| YoY Change | 25.98% | 37.75% |
| Income Tax | -$197.0K | -$45.00K |
| % Of Pretax Income | ||
| Net Earnings | -$1.219M | -$1.079M |
| YoY Change | 12.97% | 36.07% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$332.4K | -$337.5K |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q3 | 2016 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $940.0K | $1.230M |
| YoY Change | -23.58% | -31.28% |
| Cash & Equivalents | $943.0K | $1.229M |
| Short-Term Investments | ||
| Other Short-Term Assets | $250.0K | $160.0K |
| YoY Change | 56.25% | 220.0% |
| Inventory | ||
| Prepaid Expenses | $250.0K | $164.0K |
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $1.533M | $1.646M |
| YoY Change | -6.87% | -15.93% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | ||
| YoY Change | ||
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | ||
| YoY Change | ||
| Total Long-Term Assets | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $1.533M | $1.646M |
| Total Long-Term Assets | $0.00 | $0.00 |
| Total Assets | $1.533M | $1.646M |
| YoY Change | -6.87% | -19.35% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $874.0K | $1.069M |
| YoY Change | -18.24% | 67.55% |
| Accrued Expenses | $1.218M | $693.0K |
| YoY Change | 75.76% | 2135.48% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $250.0K |
| YoY Change | -100.0% | 0.0% |
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $2.149M | $2.082M |
| YoY Change | 3.22% | 126.55% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $300.0K | $292.0K |
| YoY Change | 2.74% | -2.67% |
| Other Long-Term Liabilities | $90.00K | $50.00K |
| YoY Change | 80.0% | 25.0% |
| Total Long-Term Liabilities | $1.483M | $3.069M |
| YoY Change | -51.68% | -1.35% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $2.149M | $2.082M |
| Total Long-Term Liabilities | $1.483M | $3.069M |
| Total Liabilities | $3.632M | $5.151M |
| YoY Change | -29.49% | 27.82% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$26.99M | -$16.54M |
| YoY Change | 63.18% | 27.84% |
| Common Stock | $4.000K | $32.00K |
| YoY Change | -87.5% | 6.67% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$2.099M | -$3.505M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $1.533M | $1.646M |
| YoY Change | -6.87% | -19.35% |
Cashflow Statement
| Concept | 2017 Q3 | 2016 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$1.219M | -$1.079M |
| YoY Change | 12.97% | 36.07% |
| Depreciation, Depletion And Amortization | ||
| YoY Change | ||
| Cash From Operating Activities | -$250.0K | -$940.0K |
| YoY Change | -73.4% | 6.82% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | ||
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | |
| YoY Change | -100.0% | |
| Cash From Investing Activities | $0.00 | |
| YoY Change | -100.0% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 0.000 | 270.0K |
| YoY Change | -100.0% | -76.92% |
| NET CHANGE | ||
| Cash From Operating Activities | -250.0K | -940.0K |
| Cash From Investing Activities | 0.000 | |
| Cash From Financing Activities | 0.000 | 270.0K |
| Net Change In Cash | -250.0K | -670.0K |
| YoY Change | -62.69% | -184.81% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$250.0K | -$940.0K |
| Capital Expenditures | ||
| Free Cash Flow | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
406000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
410000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
131000 | ||
| snbp |
Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
|
19000 | ||
| CY2017Q3 | snbp |
Common Shares Issued Upon Conversion Of Notes Payable
CommonSharesIssuedUponConversionOfNotesPayable
|
315356 | |
| snbp |
Debt Conversion Conversion Of Demand Notes Into Common Stock
DebtConversionConversionOfDemandNotesIntoCommonStock
|
250000 | ||
| snbp |
Debt Conversion Conversion Of Demand Notes Into Common Stock
DebtConversionConversionOfDemandNotesIntoCommonStock
|
|||
| snbp |
Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock
|
2888000 | ||
| snbp |
Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock
|
|||
| snbp |
Deferred Compensation Exchanged For Common Stock And Warrants
DeferredCompensationExchangedForCommonStockAndWarrants
|
|||
| snbp |
Deferred Compensation Exchanged For Common Stock And Warrants
DeferredCompensationExchangedForCommonStockAndWarrants
|
196000 | ||
| CY2017Q3 | snbp |
Grant Agreement Total Grants
GrantAgreementTotalGrants
|
225000 | |
| CY2017Q3 | snbp |
Grant Income Nonoperating
GrantIncomeNonoperating
|
27000 | |
| CY2016Q3 | snbp |
Grant Income Nonoperating
GrantIncomeNonoperating
|
||
| snbp |
Grant Income Nonoperating
GrantIncomeNonoperating
|
110000 | ||
| snbp |
Grant Income Nonoperating
GrantIncomeNonoperating
|
|||
| snbp |
Increase Decrease In Income And Other Taxes Receivable
IncreaseDecreaseInIncomeAndOtherTaxesReceivable
|
-9000 | ||
| snbp |
Increase Decrease In Income And Other Taxes Receivable
IncreaseDecreaseInIncomeAndOtherTaxesReceivable
|
-512000 | ||
| CY2017Q3 | snbp |
Interest Payable Noncurrent
InterestPayableNoncurrent
|
87000 | |
| CY2016Q4 | snbp |
Interest Payable Noncurrent
InterestPayableNoncurrent
|
||
| snbp |
Intrinsic Value Of Convertible Debt With Conversion Feature
IntrinsicValueOfConvertibleDebtWithConversionFeature
|
2954000 | ||
| snbp |
Intrinsic Value Of Convertible Debt With Conversion Feature
IntrinsicValueOfConvertibleDebtWithConversionFeature
|
|||
| snbp |
Noncash Interest Expense
NoncashInterestExpense
|
87000 | ||
| snbp |
Noncash Interest Expense
NoncashInterestExpense
|
9000 | ||
| CY2017Q3 | snbp |
Proceeds From Incentive Payment Received
ProceedsFromIncentivePaymentReceived
|
460000 | |
| snbp |
Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
|
4000 | ||
| snbp |
Sharebased Goods And Nonemployee Services Transaction Compensation Expense
SharebasedGoodsAndNonemployeeServicesTransactionCompensationExpense
|
397000 | ||
| snbp |
Sharebased Goods And Nonemployee Services Transaction Compensation Expense
SharebasedGoodsAndNonemployeeServicesTransactionCompensationExpense
|
0 | ||
| snbp |
Stock Issued During Period Value Conversion Of Demand Notes Payable
StockIssuedDuringPeriodValueConversionOfDemandNotesPayable
|
993000 | ||
| CY2017Q3 | snbp |
Working Capital
WorkingCapital
|
-616000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1167000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
|||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
961000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
|||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
53000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
21000 | ||
| CY2017Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
874000 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1245000 | |
| CY2017Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1218000 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
842000 | |
| CY2017Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-170000 | |
| CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
76000 | |
| CY2017Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
25059000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
14058000 | |
| us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
2954000 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1167000 | ||
| CY2017Q3 | us-gaap |
Assets
Assets
|
1533000 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
877000 | |
| CY2017Q3 | us-gaap |
Assets Current
AssetsCurrent
|
1533000 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
877000 | |
| CY2017Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
943000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
438000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
925000 | |
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1229000 | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
505000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
304000 | ||
| CY2017Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
351500 | |
| CY2017Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q3 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
2461216 | |
| CY2017Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2017Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
3670443 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
3220111 | |
| CY2017Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
3670443 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
3220111 | |
| CY2017Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
| CY2017Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1281000 | |
| CY2016Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1140000 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-8459000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-2968000 | ||
| CY2017Q3 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
1096000 | |
| CY2016Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
||
| CY2017Q3 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
||
| CY2016Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
2733000 | |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.33 | |
| CY2016Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.34 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.33 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.94 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
18000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
1000 | ||
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y73D | ||
| CY2017Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
1100000 | |
| CY2017Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
515000 | |
| CY2016Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
499000 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2252000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1399000 | ||
| CY2017Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-1416000 | |
| CY2016Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-1124000 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-8673000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-3126000 | ||
| CY2017Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-197000 | |
| CY2016Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-45000 | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-460000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-252000 | ||
| CY2017Q3 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
340000 | |
| CY2016Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
321000 | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-654000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
377000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
25000 | ||
| us-gaap |
Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
|
3696000 | ||
| CY2017Q3 | us-gaap |
Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
|
||
| CY2016Q3 | us-gaap |
Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
|
||
| us-gaap |
Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
|
|||
| CY2017Q3 | us-gaap |
Interest Expense
InterestExpense
|
474000 | |
| CY2016Q3 | us-gaap |
Interest Expense
InterestExpense
|
45000 | |
| us-gaap |
Interest Expense
InterestExpense
|
1145000 | ||
| us-gaap |
Interest Expense
InterestExpense
|
135000 | ||
| us-gaap |
Interest Paid
InterestPaid
|
5000 | ||
| us-gaap |
Interest Paid
InterestPaid
|
70000 | ||
| CY2017Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
57000 | |
| CY2016Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
155000 | |
| CY2017Q3 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
1000 | |
| CY2016Q3 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
||
| us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
1000 | ||
| us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
2000 | ||
| CY2017Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1533000 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
877000 | |
| CY2017Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2149000 | |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5519000 | |
| CY2017Q3 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
1483000 | |
| CY2016Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
||
| CY2017Q3 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
||
| CY2016Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
294000 | |
| CY2017Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
300000 | |
| CY2016Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"><div style=" margin: 0pt; text-align: left; font-size: 10pt; font-family: Times New Roman,Times,serif;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> </div></div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-size: 10pt; font-family: Times New Roman,Times,serif;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">Risks and Uncertainties</div></div></div> </td> </tr> </table> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration (“TGA”) in Australia, the European Medicines Agency (“EMA”) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take many years, and is normally expected to involve substantial expenditures.</div> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> incurred losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$27.0</div> million since our inception in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>we incurred a net loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.2</div> million, which includes a non-cash charge of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.7</div> million related to the induced conversion of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.9</div> million of convertible promissory notes and accrued interest, originally issued in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000</div> of demand notes, originally issued in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2015, </div>into shares of our common stock. We also incurred negative cash flows from operating activities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.6</div> million for this period. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue development activities and seek to commercialize our initial product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101</div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>we had cash and cash equivalents of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$943,000,</div> negative working capital of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$616,000</div> and a stockholders’ deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.1</div> million. The Company’s principal sources of cash have historically included the issuance of convertible debt and equity securities. </div></div> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">condensed consolidated financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed<div style="display: inline; font-weight: bold;"> </div>consolidated financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our current independent registered public accounting firm, included a paragraph emphasizing this going concern uncertainty in their audit report covering our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> financial statements dated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 30, 2017. </div>Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101</div> product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101</div> product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div> titled “<div style="display: inline; font-style: italic;">Liquidity and Management’s Plans</div>.”</div></div></div> | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3106000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1873000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2619000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1570000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-27000000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-8213000 | ||
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1219000 | |
| CY2016Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1079000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-2874000 | ||
| CY2017Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-371000 | |
| CY2016Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
11000 | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-4466000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-70000 | ||
| CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1045000 | |
| CY2016Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1135000 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4207000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3056000 | ||
| CY2017Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-62000 | |
| CY2016Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-61000 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-246000 | ||
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-94000 | ||
| CY2017Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
75000 | |
| CY2016Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
56000 | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
264000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
63000 | ||
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
16000 | ||
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
16000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
152000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
152000 | ||
| CY2017Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2017Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2017Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2017Q3 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
250000 | |
| CY2016Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
118000 | |
| CY2017Q1 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
3100000 | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
|||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
10.10 | ||
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
1114400 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
|||
| us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
3059000 | ||
| us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
|||
| us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
|||
| us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
1873000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
28000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
|||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
19000 | ||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
|||
| CY2017Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
530000 | |
| CY2016Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
636000 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1955000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1657000 | ||
| CY2017Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-26992000 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-18779000 | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1167000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
|||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
|||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
|||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
|||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
|||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
|||
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
1110400 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
4000 | ||
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
3896235 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2121985 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
701960 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
683960 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.50 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.77 | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.25 | ||
| CY2017Q3 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
490410 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
|||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
|||
| us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
|
P7Y302D | ||
| CY2017Q3 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
9.77 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
683960 | |
| CY2016Q3 | us-gaap |
Share Price
SharePrice
|
||
| us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P7Y350D | ||
| us-gaap |
Stock Issued1
StockIssued1
|
|||
| us-gaap |
Stock Issued1
StockIssued1
|
75000 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
22000 | ||
| us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
5841000 | ||
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
28000 | ||
| CY2017Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-2099000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-4642000 | |
| CY2017Q3 | us-gaap |
Unsecured Debt Current
UnsecuredDebtCurrent
|
||
| CY2016Q4 | us-gaap |
Unsecured Debt Current
UnsecuredDebtCurrent
|
250000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> | ||
| CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
3670443 | |
| CY2016Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
3201700 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
3518839 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
3069195 |
